Bio

Bio


John Montgomery Yost, MD, MPH is a Clinical Associate Professor in Dermatology at Stanford Health Care and the Director of the Nail Disorders Clinic. After attending medical school at the University of Michigan, he completed his residency at the Ronald O. Perelman Department of Dermatology at New York University Langone Medical Center. His clinical and research interests include nail disorders, tumors of the nail apparatus, nail surgery, longitudinal melanonychia, brittle nail disease, and inflammatory nail disorders.

Clinical Focus


  • Dermatology
  • Nail Disorders
  • Nail Surgery
  • Longitudinal Melanonychia
  • Tumors of the Nail Apparatus

Academic Appointments


Honors & Awards


  • Fulbright Scholar - Hamburg, Germany, United States Department of State, Bureau of Educational and Cultural Affairs
  • National Medical Honor Society, Alpha Omega Alpha (2009-Present)
  • Morris Leider Award for Excellence in Dermatology, New York University Langone Medical Center The Ronald O. Perelman Department of Dermatology (2014)

Boards, Advisory Committees, Professional Organizations


  • Member, Council for Nail Disorders (2013 - Present)

Professional Education


  • Residency:New York University Dermatology ResidencyNY
  • Board Certification: Dermatology, American Board of Dermatology (2014)
  • Medical Education:University of Michigan Medical School (2010) MI
  • Internship:Oakwood Hospital and Medical CenterMI
  • Masters in Public Health, Boston University School of Public Health, Epidemiology
  • BA, Bowdoin College, Summa cum laude

Publications

All Publications


  • Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With > 50% Baseline Infection JOURNAL OF DRUGS IN DERMATOLOGY Pariser, D. M., Wendelken, M. E., Rycerz, A. M., Lowe, N., Yost, J., Lipner, S. R. 2018; 17 (2): 168–72

    Abstract

    Women with onychomycosis may suffer more effects on their quality of life than men. There is limited female-specific data on the treatment of onychomycosis. Tavaborole is a topical treatment option for onychomycosis. This post-hoc study evaluated the nail plates of women using data from the tavaborole 5% Phase III studies at baseline and end of study for the areas of healthy nail and infected nail. Over 52 weeks (48-week treatment, 4-week follow up), women treated with tavaborole had an average 32% increase in healthy nail and 21% decrease in infected nail. Patients with baseline infection involving >50% of the nail plate had an average increase in percentage of unaffected nail surface area of 81% and a corresponding 51% decrease in infected nail. These analyses suggest that patients with the greatest toenail involvement at baseline had greater overall improvements than those who were less affected. This evaluation provides additional clinical guidance for treating women with onychomycosis using tavaborole. J Drugs Dermatol. 2018;17(2):168-172.

    View details for Web of Science ID 000424534100005

    View details for PubMedID 29462224

  • Neurogenic Rosacea: A Distinct Clinical Subtype Requiring a Modified Approach to Treatment ARCHIVES OF DERMATOLOGY Scharschmidt, T. C., Yost, J. M., Truong, S. V., Steinhoff, M., Wang, K. C., Berger, T. G. 2011; 147 (1): 123-126

    View details for Web of Science ID 000286229000035

    View details for PubMedID 21242409